Use of biological treatments in patients with hidradenitis suppurativa
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Use of biological treatments in patients with hidradenitis suppurativa
Authors
Keywords
-
Journal
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Volume 29, Issue 1, Pages 56-60
Publisher
Wiley
Online
2014-03-13
DOI
10.1111/jdv.12438
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumour Necrosis Factor-alpha and Matrix Metalloproteinase-2 are Expressed Strongly in Hidradenitis Suppurativa
- (2013) E Mozeika et al. ACTA DERMATO-VENEREOLOGICA
- Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
- (2013) Alexa B. Kimball et al. ANNALS OF INTERNAL MEDICINE
- Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases
- (2013) Laurent Machet et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The off-label treatment of severe hidradenitis suppurativa with TNF-α inhibitors: a systematic review
- (2012) Dominique C. van Rappard et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Incidence of Hidradenitis Suppurativa and Associated Factors: A Population-Based Study of Olmsted County, Minnesota
- (2012) Benjamin G. Vazquez et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Hidradenitis Suppurativa
- (2012) Gregor B.E. Jemec NEW ENGLAND JOURNAL OF MEDICINE
- A Systematic Review of Treatments for Hidradenitis Suppurativa
- (2011) Henry W. Lim ARCHIVES OF DERMATOLOGY
- A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa
- (2011) I. Miller et al. BRITISH JOURNAL OF DERMATOLOGY
- Histopathologic Spectrum of Psoriasiform Skin Reactions Associated With Tumor Necrosis Factor-α Inhibitor Therapy. A Study of 16 Biopsies
- (2010) Alvaro C Laga et al. AMERICAN JOURNAL OF DERMATOPATHOLOGY
- Treatment of Hidradenitis Suppurativa With Etanercept Injection
- (2010) David R. Adams et al. ARCHIVES OF DERMATOLOGY
- A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa
- (2010) Masahiro Amano et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial
- (2010) Annika Grant et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Hidradenitis suppurativa markedly decreases quality of life and professional activity
- (2010) Łukasz Matusiak et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Increased Serum Tumour Necrosis Factor- in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor- Agents?
- (2009) L Matusiak et al. ACTA DERMATO-VENEREOLOGICA
- Long-term Successful Adalimumab Therapy in Severe Hidradenitis Suppurativa
- (2009) Ricardo Blanco et al. ARCHIVES OF DERMATOLOGY
- Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity
- (2009) K. Sartorius et al. BRITISH JOURNAL OF DERMATOLOGY
- Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study
- (2009) H.H. van der Zee et al. BRITISH JOURNAL OF DERMATOLOGY
- Hidradenitis suppurativa: A comprehensive review
- (2009) Ali Alikhan et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- European S3-Guidelines on the systemic treatment of psoriasis vulgaris
- (2009) D Pathirana et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Prevalence and factors associated with hidradenitis suppurativa: Results from two case-control studies
- (2008) Jean E. Revuz et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started